Evaluation of Efficacy and Safety of PLN-74809 in Patients With Idiopathic Pulmonary Fibrosis
Status:
Recruiting
Trial end date:
2022-04-30
Target enrollment:
Participant gender:
Summary
A Phase 2a, multicenter, 3-part, randomized, double-blind, dose-ranging, placebo-controlled
study to evaluate the safety, tolerability, and PK of once-daily treatment with PLN-74809 in
participants with idiopathic pulmonary fibrosis.